2. Endocrinology

Endocrinology

Endocrinology

Related Products

PDF 21.44 MB

Found in most species of the animal kingdom, the endocrine system consists of glands that secrete hormones, and receptors that detect and react to the hormones. In response to environmental stimuli, the endocrine system secretes hormones and uses them as chemical messengers to orchestrate physiological, developmental and reproductive changes that affect the entire body for a long period of time. In order to maintain the proper functioning of the body through its entire life cycle, the endocrine system utilizes a complex feedback mechanism to fine-tune the balance of hormones in the bloodstream. Even a slight disruption to endocrine system’s function can throw off the delicate balance of hormones in the human body and lead to an endocrine disorder, or endocrine disease, such as diabetes, adrenal insufficiency, hyper- or hypothyroidism, and polycystic ovary syndrome (PCOS).

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14297
    Milveterol 652990-07-3 98%
    Milveterol is a long-acting β(2)-adrenoceptor agonist with high binding activity. Milveterol exhibits high potency in vitro and a prolonged duration of action in a guinea pig bronchoprotection model. Milveterol has been structurally optimized to show enhanced binding potency compared to its parent monomer.
    Milveterol
  • HY-14466
    GW 848687X 612831-24-0 98%
    GW 848687X is a selective, orally active prostaglandin EP1 receptor antagonist for the inhibition of inflammatory pain. The oral bioavailability of GW 848687X was 54% in rats and 53% in dogs. GW 848687X has a half-life of 2 hours and has inhibitory potential for both acute and chronic pain.
    GW 848687X
  • HY-14752
    Ronacaleret 753449-67-1 98%
    Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis.
    Ronacaleret
  • HY-14767
    Fasobegron 643094-49-9 98%
    Fasobegron is a β3-adrenergic receptor agonist with a human EC50 of 4.8 nM. Fasobegron shows an EC50 of 250 nM for human β1-adrenergic receptors. Fasobegron can be used for the research of overactive bladder.
    Fasobegron
  • HY-14770
    Ibodutant 522664-63-7 98%
    Ibodutant (MEN 15596) is a potent and selective tachykinin NK2 receptor antagonist with a pKi of 10.1.
    Ibodutant
  • HY-14820
    Macimorelin 381231-18-1 98%
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).
    Macimorelin
  • HY-14863
    Lunacalcipol 250384-82-8 98%
    Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT).
    Lunacalcipol
  • HY-14898
    AGN 210676 910562-15-1 98%
    AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.
    AGN 210676
  • HY-14915
    Bedoradrine 194785-19-8 98%
    Bedoradrine is a highly selective β2-adrenergic agonist with activity in suppressing asthma and chronic obstructive pulmonary disease (COPD). Bedoradrine is administered by intravenous infusion and is specifically indicated for the suppression of acute asthma attacks. Bedoradrine has shown good safety and preliminary efficacy in clinical trials, especially in patients with stable moderate to severe asthma. The results of Bedoradrine studies have shown that it can provide clinical benefits without increasing clinical risks, especially for patients who are unable to use inhalation or nebulization suppression.
    Bedoradrine
  • HY-14998
    Halofenate 26718-25-2 98%
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo.
    Halofenate
  • HY-15007
    L 366509 138382-23-7 98%
    L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists.
    L 366509
  • HY-15008
    L-368,899 148927-60-0 98%
    L-368,899 is an orally active and selective OT (oxytocin ) receptor antagonist, with IC50s of 8.9 and 26 nM for uterus of rat and human, respectively. L-368,899 can cross the blood-brain barrier (BBB). L-368,899 inhibits oxytocin-stimulated uterine contractions in rats and can be used in study of preterm labor.
    L-368,899
  • HY-15016
    (E/Z)-OT-R antagonist 1 364076-99-3 98%
    (E/Z)-OT-R antagonist 1 is a mixture of E/Z forms of OT-R antagonist 1 (HY-15015). OT-R antagonist 1 is a novel, potent, selective non-peptide OT-R antagonist that inhibits oxytocin-induced intracellular Ca2+ activation (IC50 = 8 nM).
    (E/Z)-OT-R antagonist 1
  • HY-15242
    Capromorelin 193273-66-4 98%
    Capromorelin (CP 424391) is a pyrazolinone-piperidine dipeptide. Capromorelin is an orally active and potent growth hormone secretagogue (GHS) (hGHS-R1a Ki=7 nM, rat pituicyte EC50=3 nM).
    Capromorelin
  • HY-16027
    Acyline 170157-13-8 99.52%
    Acyline, a GnRH peptide analogue, is a GnRH antagonist that inhibits gonadotropin and testosterone (T) levels.
    Acyline
  • HY-16244
    GW-300 646989-21-1 98%
    GW-300 is a SREBP cleavage-activating protein (SCAP) ligand that can be used for the study of endocrinology and metabolic disease.
    GW-300
  • HY-16290
    Lonaprisan 211254-73-8 98%
    Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC50 of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect.
    Lonaprisan
  • HY-16470
    SR 16234 229634-98-4 98%
    SR 16234 (TAS-108) is a selective estrogen receptor modulator. SR 16234 is promising for research of pain symptoms associated with endometriosis.
    SR 16234
  • HY-16741
    Erlosiban 1477482-19-1 98%
    Erlosiban (OBE001) is an orally active non-peptide type oxytocin receptor antagonist. Erlosiban inhibits the increase of intracellular calcium concentration, thereby reducing uterine smooth muscle contraction. Erlosiban can be used for research on premature birth and to improve embryo implantation and pregnancy rate in assisted reproductive technology (AR).
    Erlosiban
  • HY-16778
    Etiguanfacine 1346686-31-4 98%
    Etiguanfacine is a derivative of Guanfacine (HY-17416A). Etiguanfacine can be used for research to reduce the gastrointestinal side effects of Guanfacine.
    Etiguanfacine
Cat. No. Product Name / Synonyms Application Reactivity